Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Contineum Therapeutics Inc. has two pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to two examiners and two art units, indicating separate examination channels for the current portfolio activity. SCHMIDT, IZABELA MARIA is the busiest examiner, with one pending matter.
Counsel should manage the matters independently while coordinating shared technical positions when appropriate. The separate art-unit and examiner assignments mean that a response strategy effective in one case may not address the other case’s requirements. The profile supports parallel prosecution tracking with matter-specific attention to claim scope and evidentiary needs.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHMIDT, IZABELA MARIA | 1 | 65.7% | +42.7% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 20.0% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286088 | CRYSTALLINE COMPOUND OF MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | DEKARSKE, MADELINE MCGUIRE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294513 | LPAR1 ANTAGONISTS AND USES THEREOF | SCHMIDT, IZABELA MARIA | — |
| 18286088 | CRYSTALLINE COMPOUND OF MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | DEKARSKE, MADELINE MCGUIRE | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18294513 | LPAR1 ANTAGONISTS AND USES THEREOF | SCHMIDT, IZABELA MARIA | 1621 | §112 | Non-Final OA | — | Pending | Feb 01, 2024 |
| 18286088 | CRYSTALLINE COMPOUND OF MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | DEKARSKE, MADELINE MCGUIRE | 1622 | §112Other | Non-Final OA | — | Pending | Oct 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialContineum Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Izabela Maria Schmidt has the most, with 1 of Contineum Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
